摘要
目的:探讨贝那普利在维持性血液透析患者中的应用及对胰岛素抵抗、脂代谢紊乱的影响。方法:选择2015年3月到2017年3月于我院进行维持性血液透析的85例患者进行研究,以随机数字表法分为观察组(n=45)和对照组(n=40),对照组给予维持性血液透析治疗,观察组在对照组的基础上加用贝那普利治疗。比较两组治疗后空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、结缔组织生长因子(CTGF)、内皮素-1水平的变化情况及不良反应发生情况。结果:治疗后,两组患者FINS、HOMA-IR水平均明显下降,且观察组患者FINS、HOMA-IR水平显著低于对照组,(P<0.05);治疗前,两组患者血脂各指标水平无显著差异;治疗后,两组患者血脂各指标水平均有所上升,HDL-C有所下降,观察组患者TC、TG、LDL-C水平显著低于对照组,(P<0.05),HDL-C水平比较差异无统计学意义(P>0.05);治疗前,两组患者血清CTGF、ET-1水平无显著差异;治疗后,两组患者血清CTGF、ET-1水平均明显下降,且观察组患者血清CTGF、ET-1水平显著低于对照组,(P<0.05);两组治疗期间头昏、腹泻、低血压、高钾血症总发生率分别为8.89%、22.50%,比较无显著差异(P>0.05)。结论:贝那普利在治疗维持性血液透析患者中效果显著,可有效改善患者胰岛素抵抗、脂代谢紊乱,值得临床推广应用。
Objective:To study application of benazepril in maintenance hemodialysis patients and its effects on insulin resistance and lipid metabolism disorder.Methods:85 patients who underwent maintenance hemodialysis in our hospital from March 2015 to March 2017 were selected for the study,the randomized table was divided into the observation group(n=45)and the control group(n=40).The control group was treated with maintenance hemodialysis,and the observation group was treated with benazepril on the basis of the control group.The changes of fasting insulin(FINS),insulin resistance index(homa-ir),triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(ldl-c),high-density lipoprotein cholesterol(hdl-c),connective tissue growth factor(CTGF),endothelin-1 level and adverse reactions were compared between the two groups after treatment.Results:Before treatment,there was no significant difference in the level of FINS and homa-ir between the two groups.After treatment,the levels of females and homa-ir in both groups significantly decreased,and the levels of FINS and homa-ir in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there was no significant difference in serum lipid level between the two groups.After treatment,serum lipid levels of both groups increased,and HDL-C decreased.TC,TG and ldl-c levels of the observation group were significantly lower than those of the control group(P<0.05).There was no statistically significant difference in HDL-C level(P>0.05).Before treatment,there was no significant difference in serum CTGF and et-1 level between the two groups.After treatment,the serum CTGF and et-1 levels of both groups were significantly decreased,and the serum CTGF and et-1 levels of the observation group were significantly lower than those of the control group(P<0.05).The total incidence of dizziness,diarrhea,hypotension and hyperkalemia in the two groups was 8.89%and 22.50%,respectively,without significant difference(P>0.05).Conclusion:Benazepr
作者
薛辉
闫晓辉
梁磊
王媛
XUE Hui;YAN Xiaohui;LIANG Lei(Shaanxi People's Hospital,Shaanxi Xi'an 710068,China)
出处
《河北医学》
CAS
2019年第9期1442-1446,共5页
Hebei Medicine
基金
陕西省科技攻关项目,(编号:2015SF063)
关键词
贝那普利
维持性血液透析
胰岛素抵抗
脂代谢紊乱
Benapril
Maintenance hemodialysis
Insulin resistance
Lipid metabolism disorder
